fig3
![Gemcitabine followed by radiotherapy in treatment of newly diagnosed high-grade gliomas](https://image.oaes.cc/e0539f65-3cbb-40c5-a875-5d8f87d3d926/1387.fig.3.png)
Figure 3. Subgroup analysis of PFS (depicted as Time to Progression, TTP) and OS according to surgical extension median PFS of 11 months (95% CI 8.1-13.9) for subtotal resection versus 4 months (95% CI 3.5-4.6) for a biopsied patients and median OS 15.4 months (95% CI 13.5-17.3) versus 9.5 months (95% CI 8.1-11.0) for subtotal resection versus biopsy, respectively. PFS: progression free survival; OS: overall survival